← 返回首页 markets

Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound’s cash sales

📍 feeds.marketwatch.com ⏰ 2026-03-17 22:27 🌏 US
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.

原文链接：https://www.marketwatch.com/story/lilly-gets-rare-downgrade-as-analysts-question-hype-over-glp-1-pills-and-zepbounds-cash-sales-60b231f4?mod=mw_rss_topstories